Golding BT - Search Results

1

Structure-guided design of purine-based probes for selective Nek2 inhibition.

Coxon CR, Wong C, Bayliss R, Boxall K, Carr KH, Fry AM, Hardcastle IR, Matheson CJ, Newell DR, Sivaprakasam M, Thomas H, Turner D, Yeoh S, Wang LZ, Griffin RJ, Golding BT, Cano C. Coxon CR, et al. Among authors: golding bt. Oncotarget. 2017 Mar 21;8(12):19089-19124. doi: 10.18632/oncotarget.13249. Oncotarget. 2017. PMID: 27833088 Free PMC article.

2

In vivo and ex vivo magnetic resonance spectroscopy as applied to pharmacokinetic studies with anticancer agents: a review.

Newell DR, Maxwell RJ, Golding BT. Newell DR, et al. Among authors: golding bt. NMR Biomed. 1992 Sep-Oct;5(5):273-8. doi: 10.1002/nbm.1940050514. NMR Biomed. 1992. PMID: 1449968 Review.

3

Potentiation of temozolomide-induced cytotoxicity: a comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitors.

Boulton S, Pemberton LC, Porteous JK, Curtin NJ, Griffin RJ, Golding BT, Durkacz BW. Boulton S, et al. Among authors: golding bt. Br J Cancer. 1995 Oct;72(4):849-56. doi: 10.1038/bjc.1995.423. Br J Cancer. 1995. PMID: 7547230 Free PMC article.

4

The role of inhibitors of poly(ADP-ribose) polymerase as resistance-modifying agents in cancer therapy.

Griffin RJ, Curtin NJ, Newell DR, Golding BT, Durkacz BW, Calvert AH. Griffin RJ, et al. Among authors: golding bt. Biochimie. 1995;77(6):408-22. doi: 10.1016/0300-9084(96)88154-5. Biochimie. 1995. PMID: 7578423 Review.

5

New routes to polyamine analogues.

Golding BT, Griffin RJ, Mitchinson A, O'Sullivan MC. Golding BT, et al. Biochem Soc Trans. 1994 Nov;22(4):391S. doi: 10.1042/bst022391s. Biochem Soc Trans. 1994. PMID: 7698414 No abstract available.

6

Probing the active site and mechanism of action of O6-methylguanine-DNA methyltransferase with substrate analogues (O6-substituted guanines).

Arris CE, Bleasdale C, Calvert AH, Curtin NJ, Dalby C, Golding BT, Griffin RJ, Lunn JM, Major GN, Newell DR. Arris CE, et al. Among authors: golding bt. Anticancer Drug Des. 1994 Oct;9(5):401-8. Anticancer Drug Des. 1994. PMID: 7945724 No abstract available.

7

Potentiation of anti-cancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors NU1025 and NU1064.

Bowman KJ, White A, Golding BT, Griffin RJ, Curtin NJ. Bowman KJ, et al. Among authors: golding bt. Br J Cancer. 1998 Nov;78(10):1269-77. doi: 10.1038/bjc.1998.670. Br J Cancer. 1998. PMID: 9823965 Free PMC article.

8

Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP).

Griffin RJ, Srinivasan S, Bowman K, Calvert AH, Curtin NJ, Newell DR, Pemberton LC, Golding BT. Griffin RJ, et al. Among authors: golding bt. J Med Chem. 1998 Dec 17;41(26):5247-56. doi: 10.1021/jm980273t. J Med Chem. 1998. PMID: 9857092

9

Potentiation of the cytotoxicity of thymidylate synthase (TS) inhibitors by dipyridamole analogues with reduced alpha1-acid glycoprotein binding.

Curtin NJ, Bowman KJ, Turner RN, Huang B, Loughlin PJ, Calvert AH, Golding BT, Griffin RJ, Newell DR. Curtin NJ, et al. Among authors: golding bt. Br J Cancer. 1999 Aug;80(11):1738-46. doi: 10.1038/sj.bjc.6690591. Br J Cancer. 1999. PMID: 10468290 Free PMC article.

10

Resistance-modifying agents. Part 7: 2,6-disubstituted-4,8-dibenzylaminopyrimido[5,4-d]pyrimidines that inhibit nucleoside transport in the presence of alpha1-acid glycoprotein (AGP).

Barlow HC, Bowman KJ, Curtin NJ, Calvert AH, Golding BT, Huang B, Loughlin PJ, Newell DR, Smith PG, Griffin RJ. Barlow HC, et al. Among authors: golding bt. Bioorg Med Chem Lett. 2000 Mar 20;10(6):585-9. doi: 10.1016/s0960-894x(00)00053-6. Bioorg Med Chem Lett. 2000. PMID: 10741559

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

187 results

Search Page